Search Result
Results for "
glucuronidation
" in MedChemExpress (MCE) Product Catalog:
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-W010832
-
-
-
- HY-111832
-
|
TeGG
|
UGT
|
Infection
Metabolic Disease
|
|
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC50 of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with Ki of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .
|
-
-
- HY-107850
-
|
NSC 1612; NSC 47462
|
Drug Metabolite
UGT
|
Cardiovascular Disease
Metabolic Disease
|
|
Pregnanediol (NSC 1612) is a Progesterone (HY-N0437) metabolite. Pregnanediol does not affect the transcriptional activity of UGT1A1 enhancer-promoter complex of WT and variant type. pregnanediol inhibits glucuronidation activity of G71R-UGT1A1. Pregnanediol is a cause of breast milk jaundice in carriers of G71R .
|
-
-
- HY-W040047
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Pregnanediol 3-glucuronide is the main terminal metabolite of Progesterone (HY-N0437). Pregnanediol 3-glucuronide is the metabolite of Progesterone produced in the liver through hydroxylation and glucuronidation, with high hydrophilicity and easy excretion through urine. A decrease in the level of Pregnanediol 3-glucuronide is associated with an increased risk of thyroid cancer, while an increase is associated with the state of pregnancy. Pregnanediol 3-glucuronide is of great significance in the monitoring of female reproductive health, pregnancy assessment, and the diagnosis of endocrine diseases .
|
-
-
- HY-164899
-
|
2-aminopyridine-3-carboxylic acid imidazolide
|
Transmembrane Glycoprotein
|
Cancer
|
|
2A3 (2-aminopyridine-3-carboxylic acid imidazolide) is a T cell activator that specifically binds to CEACAM6 and CEACAM5. 2A3 exhibits enzymatic activity that catalyzes the glucuronidation of specific substrates (e.g., 1-naphthol), and possesses significant cytotoxic activity. When integrated into CAR T cells or used alone, 2A3 acts by inducing cytokine release, degranulation, and direct cytotoxicity. 2A3 kills pancreatic and breast cancer cells with high target antigen expression in vitro, and significantly inhibits the growth of pancreatic cancer xenografts in vivo. 2A3 broadly targets malignant tumors with overexpressed CEACAM5, CEACAM6, or co-expressed both, and shows high expression mainly in tissues such as the liver and colon. 2A3 serves as an important research tool for the immunotherapy of pancreatic and breast cancer . 2A3 is a novel SHAPE reagent, which can be used for the analysis of RNA structure both in vitro and in vivo . 2A3 is an electrophilic chemical probe that acylates the 2'-OH in the RNA backbone. 2A3 can be used for RNA SHAPE-MaP experiments and is capable of analyzing the RNA secondary structures at single nucleotide resolution.
|
-
-
- HY-N0757
-
|
|
Akt
Bcl-2 Family
Apoptosis
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
8-O-Acetylharpagide is an orally active iridoid glycoside compound. 8-O-Acetylharpagide exhibits anti-aging activity at low doses and anticancer activity at high doses. 8-O-Acetylharpagide induces late-stage apoptosis and necrosis-like death in cancer cells, and downregulates anti-apoptotic proteins such as Akt, p-Akt and Bcl-2. 8-O-Acetylharpagide is mainly metabolized in rats via demethylation, hydrolysis and glucuronidation, and its active metabolites downregulate the AKT/NF-κB/MMP9 signaling axis. 8-O-Acetylharpagide exerts vasoconstrictive effects by activating vascular α-adrenoceptor .
|
-
-
- HY-W010820
-
-
-
- HY-139204
-
-
-
- HY-15781
-
|
|
Bacterial
|
Infection
|
|
Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N +-glucuronidation and sulfation. Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria .
|
-
-
- HY-174905
-
|
QY201
|
JAK
Cytochrome P450
|
Inflammation/Immunology
|
|
Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases .
|
-
-
- HY-137967
-
|
Genistein 7-O-glucuronide
|
Drug Metabolite
|
Metabolic Disease
|
|
Genistein 7-β-D-Glucuronide (Genistein 7-O-glucuronide) is the primary phase II metabolite of Genistein (HY-14596) in human and rat hepatocytes. Genistein 7-β-D-Glucuronide undergoes distinct deconjugation in different functional assays. Genistein 7-β-D-Glucuronide is produced via hepatic microsomal glucuronidation and shows a mild age-related increase in intrinsic clearance in male F344 rats. Genistein 7-β-D-Glucuronide can be used for research on metabolism .
|
-
-
- HY-160250
-
|
|
Fluorescent Dye
UGT
|
Metabolic Disease
|
|
UGT1A1-IN-1 is a UGT1A1 inhibitor and fluorescent probe (Ex=370 nm, Em=520 nm), with an IC50 of 1.33 μM and a Ki of 5.02 μM. UGT1A1-IN-1 is selectively glucuronidated by UGT1A1 at the bilirubin homologous binding site, and its PET effect is blocked along with this reaction, triggering fluorescence changes. UGT1A1-IN-1 can serve as a substitute for bilirubin to detect UGT1A1 activity and perform high-throughput screening of UGT1A1 modulators .
|
-
-
- HY-106405
-
|
BIA 3-202
|
COMT
|
Metabolic Disease
|
|
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
|
-
-
- HY-128749A
-
|
Calcium D-glucarate tetrahydrate
|
Endogenous Metabolite
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
-
- HY-W012426
-
|
MDBP
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
1-Piperonylpiperazine (MDBP) is metabolized by demethylenation and subsequent methylation to N-(4-hydroxy-3-methoxybenzyl)piperazine followedby partial glucuronidation or sulfation. 1-Piperonylpiperazine can alter the disposition and metabolism of 3,4-methylenedioxymethamphetamine (MDMA) in the brain and in peripheral organs. 1-Piperonylpiperazine can inhibit the MDMA-induced neurotoxicity .
|
-
-
- HY-N7372
-
|
|
Apoptosis
|
Infection
Inflammation/Immunology
|
Licoisoflavanone is an orally active isoflavane-based immunomodulator with multiple activities including antiviral, anti-inflammatory, cytoprotective and cancer cell apoptosis-inducing effects. Licoisoflavanone can be isolated from the roots and rhizomes of Glycyrrhiza uralensis Fisch. Licoisoflavanone not only enhances the body's immunity, but also effectively prevents acute respiratory distress syndrome and multiple organ damage by alleviating cytokine storm, thereby reducing the degree of inflammation. In rats, Licoisoflavanone undergoes multiple metabolic transformation processes such as glucuronidation, hydroxylation, sulfation, methylation and dehydrogenation. Licoisoflavanone has become an important candidate molecule for research on COVID-19 and related inflammatory diseases .
|
-
-
- HY-130046
-
|
16-epi-Estriol; 16β,17β-Estriol
|
UGT
Bacterial
|
Infection
Inflammation/Immunology
|
|
16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases .
|
-
-
- HY-W016034
-
|
p-Acetamidophenyl β-D-glucuronide sodium salt; p-AAPG sodium salt
|
Drug Metabolite
|
Infection
|
|
Acetaminophen glucuronide is a safe and effective
antipyretic analgesic. Acetaminophen glucuronide is potentially toxic to liver
and kidney .
|
-
-
- HY-100516
-
|
UR-8880
|
COX
Cytochrome P450
|
Inflammation/Immunology
|
|
Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC50 of 66 nM against hCOX-2, an IC50 of 1.6 μM against canine CYP2D15, and an IC50 of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .
|
-
-
- HY-172338
-
|
CHZ-N-Glc
|
Endogenous Metabolite
|
Others
|
|
Chlorzoxazone-N-glucuronide is a phase II metabolite of the skeletal muscle relaxant – Chlorzoxazone. Chlorzoxazone-N-glucuronide can be synthesized via glucuronidation of chlorozoxazone by UGT1A9 .
|
-
-
- HY-15781A
-
|
|
Bacterial
|
Infection
|
|
(R)-Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N +-glucuronidation and sulfation. (R)-Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria .
|
-
-
- HY-W040047S
-
|
|
Endogenous Metabolite
Isotope-Labeled Compounds
|
Endocrinology
|
|
Pregnanediol 3-glucuronide is the main end-metabolite of Progesterone (HY-N0437). Pregnanediol 3-glucuronide is a metabolite of Progesterone formed by hydroxylation and glucuronidation in the liver, with high hydrophilicity and easy excretion through urine. Pregnanediol 3-glucuronide excretion rate of ≥ 9 μmol/24 h can serve as biochemical evidence of ovulation. Pregnanediol 3-glucuronide reflects the quality of the luteal phase, and a level of < 7 μmol/24 h may indicate anovulation or luteal insufficiency. Pregnanediol 3-glucuronide holds significant importance in monitoring female reproductive health, assessing pregnancy, and diagnosing endocrine disorders.
|
-
-
- HY-W588241
-
-
-
- HY-W010832R
-
-
-
- HY-124364
-
|
|
HBV
Cytochrome P450
|
Infection
Metabolic Disease
|
|
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .
|
-
-
- HY-107081
-
|
|
Dopamine Receptor
UGT
|
Neurological Disease
|
|
Berupipam hemifumarate is a selective antagonist of the dopamine D1 receptor (dopamine D1 receptor). Berupipam hemifumarate is a substrate of UDP-glucuronosyltransferase (UGT) and has a high affinity for UGT enzymes but a relatively low conversion rate. The glucuronidation rate of Berupipam hemifumarate varies among different species and genders. Berupipam hemifumarate can be used for the study of psychotic disorders .
|
-
-
- HY-N8352
-
-
-
- HY-172559
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
Solifenacin N-glucuronide is a metabolite formed by direct glucuronidation of the muscarinic receptor antagonist Solifenacin (HY-A0034). The levels of Solifenacin N-glucuronide are associated with diseases such as hepatic impairment .
|
-
-
- HY-167638
-
|
4-HPR-O-glucuronide
|
Drug Metabolite
|
Cancer
|
|
Fenretinide glucuronide (4-HPR-O-glucuronide) is a metabolite formed from Fenretinide (HY-15373) through glucuronidation. The formation of Fenretinide glucuronide enhances the water solubility of Fenretinide and facilitates its excretion. Fenretinide glucuronide holds potential for research in the field of cancer .
|
-
-
- HY-15781R
-
|
|
Bacterial
Reference Standards
|
Infection
|
|
Morinidazole (Standard) is the analytical standard of Morinidazole. This product is intended for research and analytical applications. Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N+-glucuronidation and sulfation. Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria .
|
-
-
- HY-106405R
-
|
BIA 3-202 (Standard)
|
Reference Standards
COMT
|
Metabolic Disease
|
|
Nebicapone (Standard) is the analytical standard of Nebicapone. This product is intended for research and analytical applications. Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
|
-
-
- HY-W016034R
-
|
p-Acetamidophenyl β-D-glucuronide sodium salt (Standard); p-AAPG sodium salt (Standard)
|
Drug Metabolite
Reference Standards
|
Infection
|
|
Acetaminophen glucuronide (sodium salt) (Standard) is the analytical standard of Acetaminophen glucuronide (sodium salt). This product is intended for research and analytical applications. Acetaminophen glucuronide is a safe and effective
antipyretic analgesic. Acetaminophen glucuronide is potentially toxic to liver
and kidney .
|
-
-
- HY-128749AR
-
|
Calcium D-glucarate tetrahydrate (Standard)
|
Endogenous Metabolite
Reference Standards
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
-
- HY-N0757R
-
|
|
Reference Standards
Akt
Bcl-2 Family
Apoptosis
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
8-O-Acetylharpagide (Standard) is the analytical standard of 8-O-Acetylharpagide. This product is intended for research and analytical applications. 8-O-Acetylharpagide is an iridoid glycoside compound. 8-O-Acetylharpagide exhibits anti-aging activity at low doses and anticancer activity at high doses. 8-O-Acetylharpagide induces late-stage apoptosis and necrosis-like death in cancer cells, and downregulates anti-apoptotic proteins such as Akt, p-Akt and Bcl-2. 8-O-Acetylharpagide is mainly metabolized in rats via demethylation, hydrolysis and glucuronidation, and its active metabolites downregulate the AKT/NF-κB/MMP9 signaling axis. 8-O-Acetylharpagide exerts vasoconstrictive effects by activating vascular α-adrenoceptor.
|
-
-
- HY-N3989
-
|
|
Bacterial
UGT
Interleukin Related
SOD
COX
|
Infection
Inflammation/Immunology
|
|
Haplopine is a substance with anti-inflammatory, antioxidant and photoactivated antibacterial activities. It also acts as an inhibitor of UGT1A7 and a photoactivated restriction endonuclease inhibitor. Haplopine inhibits the mRNA/protein expression of IL-6, TSLP, GM-CSF, G-CSF, IL-4, IL-13 and COX-2, while upregulating the mRNA/protein expression of SOD, CAT and HO-1. Haplopine inhibits the glucuronidation reaction catalyzed by UGT1A7 through competitive hydrophobic binding. Haplopine exerts photoactivated restriction endonuclease inhibitory effects by binding to DNA. Haplopine exhibits photoactivated activity against methicillin-resistant Staphylococcus aureus. Haplopine alleviates symptoms of atopic dermatitis. Haplopine can be used in research related to atopic dermatitis and methicillin-resistant Staphylococcus aureus infections .
|
-
-
- HY-100516R
-
|
UR-8880 (Standard)
|
Reference Standards
Cytochrome P450
COX
|
Inflammation/Immunology
|
|
Cimicoxib (Standard) is the analytical standard of Cimicoxib. This product is intended for research and analytical applications. Cimicoxib (UR-8880) is an orally active, blood-brain barrier-permeable COX-2 inhibitor that also exerts targeted inhibition on CYP2D15. It has an IC50 of 66 nM against hCOX-2, an IC50 of 1.6 μM against canine CYP2D15, and an IC50 of 0.056 μM against feline CYP2D15. By inhibiting the COX-2 pathway to reduce the production of thromboxane B2 and prostaglandin E2, Cimicoxib exerts antipyretic, anti-inflammatory and analgesic effects. Cimicoxib is metabolized by CYP2D15 to form demethyl-cimicoxib, undergoes glucuronidation via UDP-glucuronosyltransferases, and exhibits biphasic elimination kinetics in beagle dogs. Cimicoxib is widely used in studies of inflammatory diseases, osteoarthritis, and perioperative pain associated with orthopedic or soft tissue surgeries .
|
-
-
- HY-W006081
-
|
|
UGT
|
Others
|
|
3-Methyl-2-nitrophenol is a UDP-glucuronyltransferase (EC 2.4.1.17) acceptor substrate that can be confirmed to undergo glucuronidation catalyzed by the enzyme to form a glucuronide conjugate. 3-Methyl-2-nitrophenol functions as a substrate for conjugation, with glucuronidation forming a glucuronide conjugate that eliminates the parent compound’s characteristic yellow color. 3-Methyl-2-nitrophenol has higher lipid solubility that contributes to high glucuronidation conversion rate, and exhibits lower absorbance at 340 nm to act as a less interfering substrate for the NADH-NAD +-linked UDP-glucuronyltransferase assay .
|
-
-
- HY-113083A
-
|
APAP-glu potassium
|
Drug Metabolite
|
Others
|
|
Acetaminophen glucuronide potassium (APAP-glu potassium) is the inactive glucuronide metabolite of Acetaminophen (HY-66005). Acetaminophen glucuronide potassium can be used as a biomarker to measure glucuronidation activity or hepatic drug metabolism capacity .
|
-
-
- HY-W777236
-
|
|
Drug Metabolite
|
Others
|
|
N-Acetyl serotonin β-D-glucuronide is a glucuronidated metabolite of N-acetylserotonin (HY-107854) and a probe metabolite for UGT1A6 activity assays.N-Acetyl serotonin β-D-glucuronide forms from N-acetyl serotonin via glucuronidation catalyzed by a UGT enzyme .
|
-
-
- HY-D3180
-
|
|
Fluorescent Dye
|
Cardiovascular Disease
Neurological Disease
|
|
CDr20 is a fluorescent chemical probe capable of crossing the blood-brain barrier. CDr20 undergoes glucuronidation catalyzed by the UDP-glucuronosyltransferase Ugt1a7c, which triggers a fluorescence turn-on response. CDr20 enables visualization of live microglial cells. CDr20 can be used for research on Alzheimer's disease, stroke, and autism .
|
-
-
- HY-182268
-
|
|
Bacterial
Interleukin Related
TNF Receptor
|
Infection
Inflammation/Immunology
|
|
Antibiofilm agent-21 is an orally active prodrug of Antibiofilm agent-20 (HY-182268) with glucuronidation. Antibiofilm agent-21 avoids absorption in the small intestine via reduced membrane permeability, improving colon delivery rate, and converts to its active form in the colon. Antibiofilm agent-21 increases colon length and reduces IL-17 and TNF-α levels in a murine DSS (HY-116282C)-induced colitis model. Antibiofilm agent-21 can be used for the research of inflammatory bowel disease .
|
-
-
- HY-N19800
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
Anhydroicaritin-3,7-di-O-glucuronide is a diglucuronide metabolite of icaritin. Anhydroicaritin-3,7-di-O-glucuronide is also a conjugated metabolite derived from prenylated flavonoids of the genus *Epimedium* in rats. In an in vitro microsomal system, Anhydroicaritin-3,7-di-O-glucuronide is mainly catalyzed by UGT1A1 and UGT1A8. Anhydroicaritin-3,7-di-O-glucuronide is generated via sequential glucuronidation at the 3-OH and 7-OH sites of icaritin, or via further conversion from monoglucuronides of icaritin .
|
-
-
- HY-182255
-
|
|
Drug Metabolite
|
Others
|
|
ED-594 is the glucuronide form of NB-506. ED-594 is one of the major metabolites of NB-506 in rat bile, mouse liver microsomes, rat liver microsomes and human liver microsomes .
|
-
-
- HY-130046R
-
|
16-epi-Estriol (Standard); 16β,17β-Estriol (Standard)
|
Endogenous Metabolite
Reference Standards
Bacterial
|
Infection
Inflammation/Immunology
|
|
16-Epiestriol (Standard) is the analytical standard of 16-Epiestriol (HY-130046). This product is intended for research and analytical applications. 16-Epiestriol (16-epi-Estriol; 16β,17β-Estriol) is a natural stereoisomer of estriol and an anti-inflammatory agent that targets UGT. The Ki values of 16-Epiestriol against human UGT1A10 and UGT2B7 are 98.1 μM and 162 μM, respectively. As a glucuronidation substrate, 16-Epiestriol can be modified at the 3-OH, 16-OH and 17-OH sites by various UGT enzymes; in liver microsomes, the modification mainly occurs at the 16-OH and 17-OH sites, while reactions take place at all three sites in intestinal microsomes. 16-Epiestriol acts on the phase II inflammatory process by blocking edema mediated by prostaglandins and leukocyte infiltration. It lacks glycogenic activity or any effect on blood glucose levels, and serves as an important candidate molecule in the research of inflammatory diseases .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D3180
-
|
|
Fluorescent Dye
|
|
CDr20 is a fluorescent chemical probe capable of crossing the blood-brain barrier. CDr20 undergoes glucuronidation catalyzed by the UDP-glucuronosyltransferase Ugt1a7c, which triggers a fluorescence turn-on response. CDr20 enables visualization of live microglial cells. CDr20 can be used for research on Alzheimer's disease, stroke, and autism .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-W010832
-
-
-
- HY-111832
-
|
TeGG
|
other families
Classification of Application Fields
Phenols
Polyphenols
Metabolic Disease
Plants
Disease Research Fields
Source Classification
|
UGT
|
|
1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC50 of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with Ki of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .
|
-
-
- HY-107850
-
-
-
- HY-W040047
-
-
-
- HY-N0757
-
-
-
- HY-W010820
-
-
-
- HY-128749A
-
-
-
- HY-N7372
-
-
-
- HY-W010832R
-
-
-
- HY-N8352
-
-
-
- HY-128749AR
-
|
Calcium D-glucarate tetrahydrate (Standard)
|
Structural Classification
Natural Products
Endogenous metabolite
Source Classification
|
Endogenous Metabolite
Reference Standards
Apoptosis
|
|
D-Glucaric acid tetrahydrate (Standard) (Calcium D-glucarate tetrahydrate (Standard)) is the analytical standard of D-Glucaric acid tetrahydrate (HY-128749A). This product is intended for research and analytical applications. D-Glucaric acid tetrahydrate (Calcium D-glucarate tetrahydrate) is an orally active end product of the mammalian D-glucuronidation pathway. D-Glucaric acid tetrahydrate is found in a variety of fruits and vegetables. D-Glucaric acid tetrahydrate induces cell Apoptosis. D-Glucaric acid tetrahydrate reduces the expression of hippocampal myelin-related genes (Mbp, Plp1). D-Glucaric acid tetrahydrate has cholesterol-lowering and anti-tumor activities. D-Glucaric acid tetrahydrate can be used in the research of neurological diseases .
|
-
-
- HY-N0757R
-
|
|
Structural Classification
other families
Iridoids
Terpenoids
Plants
Source Classification
|
Reference Standards
Akt
Bcl-2 Family
Apoptosis
Adrenergic Receptor
|
|
8-O-Acetylharpagide (Standard) is the analytical standard of 8-O-Acetylharpagide. This product is intended for research and analytical applications. 8-O-Acetylharpagide is an iridoid glycoside compound. 8-O-Acetylharpagide exhibits anti-aging activity at low doses and anticancer activity at high doses. 8-O-Acetylharpagide induces late-stage apoptosis and necrosis-like death in cancer cells, and downregulates anti-apoptotic proteins such as Akt, p-Akt and Bcl-2. 8-O-Acetylharpagide is mainly metabolized in rats via demethylation, hydrolysis and glucuronidation, and its active metabolites downregulate the AKT/NF-κB/MMP9 signaling axis. 8-O-Acetylharpagide exerts vasoconstrictive effects by activating vascular α-adrenoceptor.
|
-
-
- HY-N3989
-
-
-
- HY-W777236
-
-
-
- HY-N19800
-
|
|
Structural Classification
Flavonols
Flavonoids
Endogenous metabolite
Source Classification
|
Drug Metabolite
|
|
Anhydroicaritin-3,7-di-O-glucuronide is a diglucuronide metabolite of icaritin. Anhydroicaritin-3,7-di-O-glucuronide is also a conjugated metabolite derived from prenylated flavonoids of the genus *Epimedium* in rats. In an in vitro microsomal system, Anhydroicaritin-3,7-di-O-glucuronide is mainly catalyzed by UGT1A1 and UGT1A8. Anhydroicaritin-3,7-di-O-glucuronide is generated via sequential glucuronidation at the 3-OH and 7-OH sites of icaritin, or via further conversion from monoglucuronides of icaritin .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W040047S
-
|
|
|
Pregnanediol 3-glucuronide is the main end-metabolite of Progesterone (HY-N0437). Pregnanediol 3-glucuronide is a metabolite of Progesterone formed by hydroxylation and glucuronidation in the liver, with high hydrophilicity and easy excretion through urine. Pregnanediol 3-glucuronide excretion rate of ≥ 9 μmol/24 h can serve as biochemical evidence of ovulation. Pregnanediol 3-glucuronide reflects the quality of the luteal phase, and a level of < 7 μmol/24 h may indicate anovulation or luteal insufficiency. Pregnanediol 3-glucuronide holds significant importance in monitoring female reproductive health, assessing pregnancy, and diagnosing endocrine disorders.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: